Patents by Inventor Michael Prakesch

Michael Prakesch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230219926
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 13, 2023
    Inventors: Rima AL-AWAR, Carlos Armando ZEPEDA-VELAZQUEZ, Gennady PODA, Methvin ISAAC, David UEHLING, Brian WILSON, Babu JOSEPH, Yong LIU, Pandiaraju SUBRAMANIAN, Ahmed MAMAI, Michael PRAKESCH, Julia Katheleen STILLE
  • Patent number: 11518764
    Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: December 6, 2022
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
  • Patent number: 11319299
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: May 3, 2022
    Assignee: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai, Michael Prakesch, Julia Kathleen Stille
  • Publication number: 20200331921
    Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Application
    Filed: February 6, 2019
    Publication date: October 22, 2020
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Lain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
  • Publication number: 20190112290
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: March 1, 2017
    Publication date: April 18, 2019
    Applicant: PROPELLON THERAPEUTICS INC.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai, Michael Prakesch, Julia Kathleen Stille